Tim Smith

This online diagnostic tool’s implementation among study participants led to increased confidence in making diagnoses of chronic plaque psoriasis.

This analysis indicates that patients with a history of a first melanoma are at risk for subsequent development of melanoma regardless of their race or their ethnicity.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

This research letter suggests that direct GOC may be considered efficacious for pediatric patients reporting non-severe symptoms which are skin-limited during a macrolide treatment.

While this analysis found social anhedonia may be a potential intervention for some, nonsocial cognition may have a significant role in social disconnection for those with schizophrenia.

These data suggest that relapse among those with schizophrenia may be common 6 months after ECT, with more than half of patients likely to experience relapse within 2 years.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

These findings highlight the underrepresentation of Black and Hispanic food allergy clinical trial participants and raise concerns about the generalizability of clinical research findings.

This Month in Review article featured a variety of notable updates in the field of pulmonology covered in September 2024.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

These new data provide additional evidence for a range of benzene concentrations detected by in over-the-counter drug products with BPO maintained at room temperature.

The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New Drug Application.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.

In this latest edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news, we highlight updates from across therapeutic pipelines.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from Maui Derm NP+PA Fall 2024 in Nashville.

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

Individuals with comorbid asthma and food allergies saw no loss of efficacy in this post hoc analysis, suggesting omalizumab’s potential for such patients.

The phase 3b/4 findings from PSORIATYK SCALP suggest that oral deucravacitinib led to significant improvements for patients with scalp psoriasis.

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

These new data demonstrate that bimekizumab was both effective and well-tolerated over the course of 2 years for patients with hidradenitis suppurativa.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD.

These new data were announced by Celldex Therapeutics regarding the sustained and deepening efficacy of barzolvolimab treatment of chronic spontaneous urticaria.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.